3-苯甲酰基氨基-3-(4-氟苯基)丙酸 | 1647-94-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-苯甲酰基氨基-3-(4-氟苯基)丙酸
• 英文名称: 3-benzamido-3-(4-fluorophenyl)propanoic acid
• 英文别名: 3-benzoylamino-3-(4-fluoro-phenyl)-propionic acid；3-Benzoylamino-3-(4-fluor-phenyl)-propionsaeure
• CAS: 1647-94-5
• 化学式: C₁₆H₁₄FNO₃
• 分子量: 287.29
• InChiKey: WLUWCIYANRIZHX-UHFFFAOYSA-N

物化性质

• 熔点：
  191.6-193.1 °C
• 沸点：
  528.3±45.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-苯甲酰基氨基-3-(4-氟苯基)丙酸 在 盐酸 、 异丁基硼酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 正己烷 、 二氯甲烷 、 水 为溶剂， 生成 (R)-1-[3-benzamido-3-(4-fluorophenyl)propanamido]-3-methylbutylboronic acid
  参考文献：
  名称：

  Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from β-Amino Acids

  摘要：

  An extensive structure-activity relationship (SAR) study of 72 dipeptidyl boronic acid proteasome inhibitors constructed from beta-amino acids is reported. SAR analysis revealed that bicyclic groups at the RI position, 3-F substituents at the R-2 position, and bulky aliphatic groups at the R-3 position were favorable to the activities. Enzymatic screening results showed that compound 78, comprising all of these features, was the most active inhibitor against the 20S human proteasome at less than a 2 nM level, as active as the marketed drug bortezomib. Cellular assays confirmed that compound 78 was the most potent against two hematologic and some solid tumor cells with IC50 values less than 1 mu M. Pharmacokinetic profiles suggested that 78 showed higher plasma exposure and a longer half-life than bortezomib.

  DOI：

  10.1021/jm1009742
• 作为产物：
  描述：

  3-氨基-3-(4-氟苯基)丙酸 在 氯化亚砜 、 水 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 四氯化碳 、 丙酮 为溶剂， 生成 3-苯甲酰基氨基-3-(4-氟苯基)丙酸
  参考文献：
  名称：

  Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from β-Amino Acids

  摘要：

  An extensive structure-activity relationship (SAR) study of 72 dipeptidyl boronic acid proteasome inhibitors constructed from beta-amino acids is reported. SAR analysis revealed that bicyclic groups at the RI position, 3-F substituents at the R-2 position, and bulky aliphatic groups at the R-3 position were favorable to the activities. Enzymatic screening results showed that compound 78, comprising all of these features, was the most active inhibitor against the 20S human proteasome at less than a 2 nM level, as active as the marketed drug bortezomib. Cellular assays confirmed that compound 78 was the most potent against two hematologic and some solid tumor cells with IC50 values less than 1 mu M. Pharmacokinetic profiles suggested that 78 showed higher plasma exposure and a longer half-life than bortezomib.

  DOI：

  10.1021/jm1009742

文献信息

• [EN] GRANZYME B DIRECTED IMAGING AND THERAPY<br/>[FR] IMAGERIE DU GRANZYME B ET THÉRAPIE DIRIGÉES CONTRE LE GRANZYME B
  申请人：CYTOSITE BIOPHARMA INC

  公开号：WO2019160916A1

  公开（公告）日：2019-08-22

  Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.

  本文提供了用于成像Granzyme B的杂环化合物。还提供了成像Granzyme B的方法、联合疗法以及包含Granzyme B成像试剂的试剂盒。
• GRANZYME B DIRECTED IMAGING AND THERAPY
  申请人：Cytosite Biopharma Inc.

  公开号：EP3752145A1

  公开（公告）日：2020-12-23
• [EN] TREATMENT FOR LIVER REGENERATION<br/>[FR] TRAITEMENT DE RÉGÉNÉRATION DU FOIE
  申请人：XENEXUS PHARMACEUTICALS PTY LTD

  公开号：WO2020014726A1

  公开（公告）日：2020-01-23

  Disclosed are pharmaceutical compositions comprising rebamipide together with one or more pharmaceutically acceptable carriers, diluents and excipients. Methods for use of the said compositions for increasing liver regeneration after partial hepatectomy and following liver transplantation to prevent postoperative liver failure and in the treatment of acute and chronic lilver failure are also disclosed.